3DAS N, DHANAWAT M, DASH B, et al. Co- drug. An efficient approach for drug optimization [J].European Journal of Pharmaceutical Sciences, 2010, 41: 571-588.
4HARTMUT M L. Rational antibiotic therapy and the position of ampicillin/sulbactam [J]. Interna- tional Journal of Antimicrobial Agents , 2008, 32: 10-28.
5BETROSIAN A P, DOUZINAS E E. Ampicillin- sulbactam: an update on the use of parenteral and oral forms in bacterial infections [J]. Expert Opin- ion on Drug Metabolism & Toxicology, 2009, 5:1 099-1 112.
6SCHLITZ W. Efficacy and safety of sultamicillin (750 mg bid) compared with amoxycillin clavu- lanate (625 mg tid) in patients with uncomplicat- ed urinary tract infections [J]. International Journal of Antimicrobial Agents, 1996, 6: S55-S59.
7PARAG S S, SHRIKANT A S, REKHA S S. Clavulanic acid: A review [J]. Biotechnology Advances, 2008, 26: 335-351.
8VUNDAVILLI J K, BADARINADH G P, PA- VAN K S R, et al. Identification, isolation and characterization of a new degradation product in sultamicillin drug substance [J]. Journal of Phar- maceutical and Biomedical Analysis, 2011, 54:582-587.
9LAVIANA L, FERNA NDEZ-MARI F, BAY- OD M, et al. HPLC for in-process control in the production of sultamicillin [J]. Journal of Phar- maceutical and Biomedical Analysis, 2003, 31: 321-328.
10ARGEKAR A P, KUNJIR S S. Quantitative es- timation of suhamicilln p-toluenesulfonate in pharmaceutical preparations by reverse-phase high performance liquid chromatography[J]. Journal of Pharmaceutical and Biomedical Analy- sis, 1996, 15: 423-427.
